East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-18

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study

NCT02771665

Case Control Study

COMPLETED

RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer

NCT04972448

Breast Cancer Recurrence

NOT_YET_RECRUITING

The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients

NCT02669745

Chinese

COMPLETED

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

NCT05079074

Metastatic Breast Cancer Circulating Tumor DNA Gene Abnormality

COMPLETED

Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery

NCT06595966

Breast Cancer Measurable Residual Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PAM50

PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Aged more than 20-year-old at the time of informed consent.
* 2\. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer.
* 3\. Have radiological or objective evidence of breast tumor size ≥1 cm.
* 4\. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue.
* 5\. Be able to sign an informed consent.

Exclusion Criteria

* 1\. Have histologically confirmed ductal carcinoma in situ (DCIS).
* 2\. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy.
* 3\. Stage IV or metastatic breast cancer patients who have received chemotherapy.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No